Advertisement
|
FDG-PET in Hodgkin lymphoma
C. Kobe1; M. Dietlein1; C. Mauz-Körholz2; A. Engert3,4; P. Borchmann3,4; O. Sabri5; O. Schober6; H. Schicha1; R. Kluge5
1Klinik und Poliklinik für Nuklearmedizin; 3Klinik I für Innere Medizin; 4Deutsche Hodgkin Studiengruppe (GHSG); 1,3,4Universität zu Köln; 2Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle-Wittenberg, Halle; 5,6Klinik und Poliklinik für Nuklearmedizin; 5Universität Leipzig; 6Universitätsklinikum Münster; Germany
Summary
The high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now. Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy. Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy. The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.Keywords
PET, Hodgkin lymphoma, radiotherapy, chemotherapy, response-adapted design
DOI
http://dx.doi.org/10.3413/nukmed-0216You may also be interested in...
| 1. | ||
J. O. Staak (1) , M. Dietlein (2) , A. Engert (1) , M. R. Weihrauch (1) , K. Schomäcker (2) , Th. Fischer (2) , W. Eschner (2) , P. Borchmann (1) , V. Diehl (1) , H. Schicha (2) , R. Schnell (1) Nuklearmedizin 2003 42 1: 19-24 | ||
| 2. | ||
C. Sucker, M. Stockschläder, G. Dölken Die Medizinische Welt 2003 54 4: 88- | ||
| 3. | ||
U. Schlegel (1) Nervenheilkunde 2010 29 11: 747-752 | ||
